Literature DB >> 27296831

Is there a role for opioids in the treatment of fibromyalgia?

Geoffrey O Littlejohn1, Emma K Guymer1, Gene-Siew Ngian1.   

Abstract

The use of opioids for chronic pain has increased significantly due to a combination of the high patient burden of pain and the more widespread availability of a range of long-acting opioid preparations. This increased opioid use has translated into the care of many patients with fibromyalgia. The pain mechanism in fibromyalgia is complex but does not seem to involve disturbance of opioid analgesic functions. Hence, there is general concern about the harms in the absence of benefits of opioids in this setting. There is no evidence that pure opioids are effective in fibromyalgia but there is some evidence that opioids with additional actions on the norepinephrine-related pain modulatory pathways, such as tramadol, can be clinically useful in some patients. Novel actions of low-dose opioid antagonists may lead to better understanding of the role of opioid function in fibromyalgia.

Entities:  

Keywords:  codeine; fibromyalgia; morphine; naltrexone; opioids; oxycodone; tapentadol; tramadol

Mesh:

Substances:

Year:  2016        PMID: 27296831     DOI: 10.2217/pmt-2016-0012

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  5 in total

Review 1.  Treatment of fibromyalgia.

Authors:  Richard Kwiatek
Journal:  Aust Prescr       Date:  2017-10-03

2.  Thalamocortical bistable switch as a theoretical model of fibromyalgia pathogenesis inferred from a literature survey.

Authors:  Ilaria Demori; Giulia Giordano; Viviana Mucci; Serena Losacco; Lucio Marinelli; Paolo Massobrio; Franco Blanchini; Bruno Burlando
Journal:  J Comput Neurosci       Date:  2022-07-11       Impact factor: 1.453

Review 3.  Modulation of NMDA Receptor Activity in Fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Biomedicines       Date:  2017-04-11

Review 4.  Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product.

Authors:  Joseph V Pergolizzi; Robert Taylor; Jo Ann LeQuang; Robert B Raffa
Journal:  J Pain Res       Date:  2018-02-08       Impact factor: 3.133

5.  Body Reprogramming: Reframing the Fibromyalgia narrative and providing an integrative therapeutic model.

Authors:  Anthony Fitzdonald Davies; Patrick Hill; Daniel Fay; Annily Dee; Cosima Locher
Journal:  Health Psychol Open       Date:  2020-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.